Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Saroja Pharma Industries India's ROE % for the quarter that ended in Mar. 2025 was 6.82%. Saroja Pharma Industries India's PB Ratio for the quarter that ended in Mar. 2025 was 0.97.
Saroja Pharma Industries India's ROE % Adjusted to Book Value for the quarter that ended in Mar. 2025 was 7.03%.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Saroja Pharma Industries India ROE % Adjusted to Book Value Chart
Saroja Pharma Industries India Annual Data
Trend
Mar21
Mar22
Mar23
Mar24
Mar25
ROE % Adjusted to Book Value
0.00
0.00
0.00
9.27
7.03
Saroja Pharma Industries India Semi-Annual Data
Mar21
Mar22
Mar23
Mar24
Mar25
ROE % Adjusted to Book Value
0.00
0.00
0.00
9.27
7.03
NSE:SAROJA vs ZTS: ROE % Adjusted to Book Value Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Saroja Pharma Industries India's ROE % Adjusted to Book Value, along with its competitors' market caps and ROE % Adjusted to Book Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Saroja Pharma Industries India ROE % Adjusted to Book Value vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Saroja Pharma Industries India's ROE % Adjusted to Book Value distribution charts can be found below:
* The bar in red indicates where Saroja Pharma Industries India's ROE % Adjusted to Book Value falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a ROE % Adjusted to Book Value of 7.03% mean?
Saroja Pharma Industries India (NSE:SAROJA) has a ROE % Adjusted to Book Value of 7.03% as of Mar. 2025. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Saroja Pharma Industries India and its competitors.
Is Saroja Pharma Industries India's ROE % Adjusted to Book Value too high?
Saroja Pharma Industries India's current ROE % Adjusted to Book Value is 7.03%. Overall, Saroja Pharma Industries India has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Saroja Pharma Industries India's ROE % Adjusted to Book Value compare to ZTS?
Saroja Pharma Industries India's ROE % Adjusted to Book Value of 7.03% can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROE % Adjusted to Book Value for a Drug Manufacturers company?
A good ROE % Adjusted to Book Value depends on the Drug Manufacturers industry context. However, ROE % Adjusted to Book Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROE % Adjusted to Book Value mean?
A high ROE % Adjusted to Book Value can signal that a stock is expensive relative to its fundamentals. Return on equity adjusted to book is the ratio of return on equity to price-book ratio. View historical data on Saroja Pharma Industries India and its competitors. Saroja Pharma Industries India's current ROE % Adjusted to Book Value is 7.03%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Saroja Pharma Industries India stock overvalued right now?
Saroja Pharma Industries India (NSE:SAROJA) has a current ROE % Adjusted to Book Value of 7.03%. The current ROE % Adjusted to Book Value is 7.03%. Saroja Pharma Industries India's overall GF Score™ is 15/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROE % Adjusted to Book Value calculated?
ROE % Adjusted to Book Value is calculated from a company's financial statements. For Saroja Pharma Industries India (NSE:SAROJA), the current ROE % Adjusted to Book Value is 7.03% as of Mar. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Saroja Pharma Industries India Ltd is a company engaged in the pharmaceutical and healthcare sector. The company trades in pharmaceutical active pharmaceutical ingredients, pharma intermediates, chemicals, and solvents used for pharmaceutical products, including human and veterinary medicines. The company has only one reportable business segment, which is pharma chemicals, such as thionyl chloride and pharmaceutical intermediates. Geographically, it operates in India, Asia Pacific, Europe, and other regions, with the majority of its revenue generated from India.
15GF Score
Get the complete analysis for NSE:SAROJA
ROE % Adjusted to Book Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:SAROJA has been successfully added to your 
